Thursday, July 15

The Journal Of Neurotherapy Announces Neurofeedback To Be An Efficacious And Specific Modality For The Treatment Of ADHD

Treatment Of ADHD
The Journal of Neurotherapy announces the publication of "A Position Paper on Neurofeedback for the Treatment of ADHD," in which the authors demonstrate that neurofeedback is a safe and efficacious treatment intervention for AD/HD, meeting a rating level of 5: Efficacious and Specific. The issue 14(2) of the journal is available online here.

The authors, Leslie Sherlin, PhD, Martijn Arns, MSc, Joel Lubar, PhD and Estate Sokhadze, PhD, reviewed over 40 studies which support the claim of level 5 efficacy and made recommendations for treatment and future study. These studies utilized different neurofeedback modalities and compared to different control groups, including medication. The neurofeedback modalities of theta/beta ratio and slow cortical potential training were represented most frequently. Most of these studies looked at impulse control, attention and hyperactivity measures. Impulse control and attention issues seem to be best remediated with neurofeedback training.

The International Society for Neurofeedback and Research (ISNR) is pleased with these findings and hopes that they help in further promoting the neurofeedback modality to the medical and psychological communities and also encourage third party payers to consider neurofeedback as a viable modality for reimbursement.

Neurofeedback uses monitoring devices to provide moment-to-moment brain wave information back to the client. This self-regulation modality is non-invasive and may be a good alternative to medication. Research demonstrates that neurofeedback is also an effective intervention for Epilepsy. Ongoing research is investigating the effectiveness of neurofeedback for other disorders such as Autism, headaches, insomnia, anxiety, substance abuse, TBI and other pain disorders, and is promising.

View the Original article.